2020 Abstract Categories
ASH encourages those who had planned to submit abstracts for this meeting to instead submit for consideration to ASH’s Annual Meeting and Exposition, the premier event in malignant and non-malignant hematology. The abstract submission site will open on June 4, 2020.
Abstracts in the following categories will be accepted for submission for the 2020 ASH Meeting on Lymphoma Biology.
- Genetic Mechanisms Underlying Lymphomagenesis
Includes genetic driven mechanisms of pathogenesis involving lymphoid malignancies and encompasses recurrent somatic mutations and/or copy number alterations as well as heritable variation associated with lymphoma risk. - Epigenetics and Lymphoma
Includes epigenetic mechanisms that underlie lymphoma pathogenesis and/or alterations to chromatic remodeling that contribute to lymphoma initiation and/or progression. - RNA Metabolism & Pathogenesis
Includes primarily basic studies of altered RNA functions in the pathogenesis of lymphoma. Includes lymphomagenic alterations in mRNA synthesis, translation and turnover, and studies of miRNAs and ncRNAs that are associated with the pathogenesis of lymphoma. - Tumor Heterogeneity & Tumor Microenvironment Interactions
Includes studies that focus on tumor clonal evolution and intra-tumoral cellular heterogeneity involving infiltrating cells in lymphoid malignancies as well as novel strategies to dynamically and non-invasively monitor such evolution. This category also includes studies investigating the role of the tumor microenvironment in tumor biology and pathogenesis. - Signaling Pathways in Lymphoma
Includes primarily basic studies of signaling pathways associated with lymphomagenesis. Includes studies of the role of post-translational receptor modification, oncogenes and tumor suppressor genes in cellular and mouse models as well as patients. - Immunotherapies in Lymphoid Cancers
Includes studies employing novel therapies that target aspects of adaptive and innate immunity as part of their mechanism of action. - T-Cell Lymphomas & Rare Entities
Includes primarily basic studies of T-cell lymphoproliferative diseases, lymphomas of infectious etiology and other rare entities. - Biological & Targeted Therapies in Lymphoid Malignancies
Includes novel targeted treatment approaches to lymphoid malignancies, including mechanism-based combination strategies.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission